Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CPO107 |
Synonyms | |
Therapy Description |
CPO107 is a bispecific fusion protein consisting ofatumumab, an anti-CD20 antibody, linked to signal regulatory protein alpha (SIRPalpha), which targets CD20 and CD47 expressed on tumor cells, potentially leading to antibody-dependent and complement-mediated tumor cell cytotoxicity and increased tumor cell phagocytosis and anti-tumor T-cell response (NCI Drug Dictionary). |